News

PentaTr@ining holds first-ever jointly hosted course in Africa

26 Jul, 2022

The PentaTr@ining Zambia-Tanzania 2022 course was held on 18-20 July. It was Penta’s first-ever jointly hosted training course in Africa and it counted more than 200 participants with nearly 150…
Read More

Double dose of dolutegravir to treat HIV in children also being treated for tuberculosis

20 Jul, 2022

Results from a substudy of the ODYSSEY trial show that children being treated for tuberculosis (TB) and HIV at the same time can safely have the anti-HIV medicine dolutegravir twice…
Read More

2nd VERDI General Assembly highlights importance of synergies across cohorts and consortia

15 Jul, 2022

The second VERDI General Assembly took place from 28-30 June 2022, bringing together more than 70 people both online and in Padua, Italy. This hybrid meeting spotlighted the important work…
Read More

Combining Factorial and MAMS designs

06 Jul, 2022

The methodology team at the MRC Clinical Trials Unit at UCL is a key partner of Penta and has made a huge contribution to our studies on HIV. The team…
Read More

Study reveals moderate effectiveness of Pfizer-BioNTech’s Covid-19 vaccine against Omicron in children aged 5-11

30 Jun, 2022

A large study on the effectiveness of the Pfizer-BioNTech’s Covid-19 vaccine in children aged 5-11 was published in The New England Journal of Medicine. The study was conducted at Israel’s…
Read More

c4c General Assembly

30 Jun, 2022

Between 13th-15th June 2022, around 140 beneficiaries of the c4c consortium met in Ghent Belgium for the c4c General Assembly. This was the first time since 2019 that the consortium…
Read More

The D3 trial is open and recruiting fast!

30 Jun, 2022

A new trial opened in May, aiming to find out if children and young people living with HIV can take two anti-HIV medicines instead of three. The trial has already…
Read More

SHIELD trial screens first two patients

28 Jun, 2022

The first two participants of the SHIELD trial (PENTA-22) were screened by Dr. Renate Strehlau and her team at Rahima Moosa Mother and Child Hospital, Johannesburg, South Africa in June 2022.  SHIELD…
Read More

EMA updates guideline on the treatment of bacterial infections

27 Jun, 2022

The European Medicines Agency (EMA) has published the final revised guideline on the evaluation of human medicines for the treatment of bacterial infections. The revised guideline reflects the outcome of recent discussions…
Read More

The Penta Early Career Researchers (ECRs) have held the first Penta Cafè!

07 Jun, 2022

The first Penta Café, held on 19 May, was attended by ECRs from Europe and Africa who discussed ideas on the best way to get papers published, tips and learning…
Read More

PediCAP surpasses 25% patient recruitment milestone

31 May, 2022

We are pleased to announce that the PediCAP trial have successfully passed its 25% recruitment milestone with more than 400 patients successfully randomised into their arms. PediCAP will determine whether…
Read More

Penta ID Network Meeting (PIM) 2022

25 May, 2022

The Penta ID Network Meeting 2022 (PIM, 28-30 April 2022) gave our members – the Penta family – a great opportunity to meet face-to-face, after more than two years of distance due…
Read More

Youth engagement and participation in clinical trials

20 May, 2022

Involving patients in our clinical trials is of utmost importance to us. Penta is dedicated to ensuring that the young people in our trials are included at various stages of…
Read More

Penta at the Global Child Health Mini-Symposium in Oxford April 7th 2022

19 May, 2022

Penta was highly represented at the Mini-Symposium hosted by Green Templeton College – University of Oxford on the 7th of April 2022 entitled “Serving the children of the world: examining…
Read More

Penta investigates cases of acute hepatitis of unknown origin in children

18 May, 2022

On 12 May, a Rapid Communication on the reported increase of acute hepatitis of unknown origin in children was published in Eurosurveillance. The paper outlines the extent and geographical distribution…
Read More

RBDCOV initiates the first Phase III clinical trial of HIPRA’s Covid-19 vaccine in immunocompromised people

18 May, 2022

One of the objective of RBDCOV is to test whether the vaccine can reactivate or re-generate a protective immune response against the virus The RBDCOV project, in which Penta is…
Read More

Capacitating the future of research in paediatric HIV

16 May, 2022

[vc_row][vc_column][vc_column_text]By design, capacity building is a fundamental part of the UNIVERSAL project. The aim of the project’s capacity building activities are to improve the ability of African and European young…
Read More

The EPIICAL story

11 May, 2022

In 2016 the Early-treated Perinatally HIV-infected individuals: Improving Children’s Actual Life (EPIICAL) consortium began gathering scientists and clinicians specialising in paediatric HIV to work towards establishing new, scientific efforts on…
Read More
1 2 3 4 22